UPNEEQ (oxymetazoline hydrochloride) 

SELF ADMINISTRATION - OPHTHALMIC SOLUTION

Indication for Prior Authorization:

Indicated for the treatment of acquired blepharoptosis in adults

Coverage Criteria:
  • Patient is 18 years of age and older, AND
  • Prescribed by or in consultation with an ophthalmologist or optometrist, AND
  • Diagnosis of acquired blepharoptosis, AND
  • Patient has obstructed visual field in primary gaze or downgaze due to blepharoptosis, AND
  • Other treatable causes of blepharoptosis have been ruled out (e.g., recent botulinum toxin injection, myasthenia gravis), AND
  • One of the following:
    • Marginal reflex distance-1 (MRD-1) is ≤ 2 mm in primary gaze, OR
    • Marginal reflex distance-1 (MRD-1) is ≤ 2 mm in downgaze, OR
    • Superior visual field loss of at least 12 degrees or 24 percent
Reauthorization Criteria:
  • Documentation of a positive clinical response to therapy (e.g., improvement in the superior visual field, increase in Marginal reflex distance-1 [MRD-1]), AND
  • One of the following:
    • Marginal reflex distance-1 (MRD-1) is ≤ 2 mm in primary gaze, OR
    • Marginal reflex distance-1 (MRD-1) is ≤ 2 mm in downgaze, OR
    • Superior visual field loss of at least 12 degrees or 24 percent
Dosing:
  • Instill 1 drop in affected eye(s) once daily
Coverage Duration:
  • Initial: 6 weeks
  • Reauthorization: 6 weeks
Authorization is Not Covered for the Following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics Committee.

  • Requests for coverage of Upneeq®, when used solely for lifting the eyelid to improve appearance, are not authorized and will not be approved.  This use is considered cosmetic only.
Review History:
  • 10/1/2020- Original review
References:
  • Upneeq [package insert]. Bridgewater, NJ. RVL Pharmaceuticals, Inc. August 2020.
  • Cahill K, Bradley E, Meyer D et al. Functional Indications for Upper Eyelid Ptosis and Blepharoplasty Surgery. Ophthalmology. 2011;118(12):2510-2517.
  • Alsuhaibani A, Burkat C, Plemel D et al. Blepharoptosis - EyeWiki. Eyewiki.aao.org. https://eyewiki.aao.org/Blepharoptosis. Published 2020. Accessed August 31, 2020.
  • RVL Pharmaceuticals, Inc. Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis. Available from: https://clinicaltrials.gov/ct2/show/NCT02436759. NCT02436759. Accessed September 10, 2020.
  • RVL Pharmaceuticals, Inc. Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis. Available from: https://clinicaltrials.gov/ct2/show/NCT03565887. NCT03565887. Accessed September 10, 2020.

 

 

Last review date: April 20, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone